Value-based pharmaceutical design, government plans for CMS, and discussion of incentivizing high-value, low-cost care, are a few of the things to prioritize for future meetings, said Lelan Wilfong, MD, VP, Payer Relations & Value-Based Transformation, McKesson Specialty Health.